Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics and certain global rights to HUNT1, expanding its neural cell therapy pipeline. The clinical-stage H

Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics and certain global rights to HUNT1, expanding its neural cell therapy pipeline. The clinical-stage Huntington’s disease program becomes Lineage’s third candidate and deepens its stem-cell focus.